FDA Grants Approval for Mirtazapine ANDA220104 by Micro Labs
The FDA has granted approval for the ANDA220104 application for Mirtazapine submitted by Micro Labs.
Published: July 19, 2026
Updated: July 19, 2026
Author: Humanexa Intelligence
Therapeutic area: Psychiatry / Antidepressant
Company: Micro Labs
Asset: Mirtazapine
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Company
Micro Labs
Asset
Signal assessment
Signal strength
high
Confidence level
moderate
Signalhigh
Confidencemoderate
Why it matters
The FDA's approval of Micro Labs' ANDA for Mirtazapine introduces a new competitor in the antidepressant market, which could disrupt pricing and market dynamics. Portfolio teams must evaluate the implications for their Mirtazapine products and adjust strategies accordingly.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor market entry timelines and pricing strategies of Micro Labs for Mirtazapine.
Related companies & assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.